Antoine Machet

Low‐dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment‐free remission in chronic myeloid leukemia patients: Results of a retrospective study

Émilie Cayssials, José Miguel Torregrosa Diaz, Pilar Gallego‐Hernanz et al. · Cancer · 2020 · 29 citations

Medicine, Pharmacology, Pharmacotherapy +13

Response to pneumococcal vaccination in multiple myeloma

Loïc Renaud, Susanna Schraen, Guillemette Fouquet et al. · Cancer Medicine · 2019 · 24 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Dasatinib plus <scp>Peg‐Interferon</scp> alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (<scp>DASA‐PegIFN</scp> study)

Lydia Roy, Jean‐Claude Chomel, Joëlle Guilhot et al. · British Journal of Haematology · 2022 · 14 citations

Medicine, Pharmacology, Pharmacotherapy +9

Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine

Antoine Machet, Caroline Poudou, Cécile Tomowiak et al. · Blood Advances · 2022 · 12 citations · Full text

Medicine, Oncology, Pharmacology +14

S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX

John Mascarenhas, Tania Jain, Salman Otoukesh et al. · HemaSphere · 2023 · 10 citations · Full text

Medicine, Oncology, Pharmacology +14